QuidelOrtho Corp
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
QDEL$12.09+13.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
QuidelOrtho Corporation and its consolidated subsidiaries may be referred to as QuidelOrtho, the Company, we, our or us in this Quarterly Report, unless the context otherwise indicates. Throughout this Quarterly Report, we have used terms which are defined below:
| AOCI | Accumulated other comprehensive loss |
|---|---|
| CEO | Chief Executive Officer |
| CFO | Chief Financial Officer |
| CODM | Chief Operating Decision Maker |
| Combinations | Business combination consummated by Quidel and Ortho on May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel, Ortho, QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc. |
| Credit Agreement | Credit agreement, dated May 27, 2022, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and L/C issuers party thereto |
| EBITDA | Earnings Before Interest, Taxes, Depreciation and Amortization |
| EMEA | Europe, the Middle East and Africa |
| EPS | (Loss) earnings per share |
| Exchange Act | Securities Exchange Act of 1934, as amended |
| GAAP | Generally Accepted Accounting Principles in the U.S. |
| Grifols | Grifols Diagnostic Solutions, Inc. |
| IT | Information technology |
| Joint Business | Ongoing collaboration arrangement between Ortho and Grifols |
| JPAC | Japan and Asia Pacific |
| OCI | Other comprehensive (loss) income |
| Ortho | Ortho Clinical Diagnostics Holdings plc |
| Quarterly Report | Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 |
| Quidel | Quidel Corporation |
| R&D | Research and development |
| Revolving Credit Facility | $800.0 million revolving credit facility under the Credit Agreement |
| RSU | Restricted Stock Unit |
| RSV | Respiratory Syncytial Virus |
| SEC | Securities and Exchange Commission |
| Securities Act | Securities Act of 1933, as amended |
| SOFR | Secured Overnight Financing Rate |
| Stock Repurchase Program | A stock repurchase program allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024, which was authorized by our Board of Directors on August 17, 2022 |
| Term Loan | $2,750.0 million senior secured term loan facility under the Credit Agreement |
| U.K. | United Kingdom |
| U.S. | United States |
| USD | United States Dollar |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.